Literature DB >> 15082589

Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

T Kirkegaard1, A Hansen, E Bruun, J Brynskov.   

Abstract

BACKGROUND: Fistulae are a troublesome complication of Crohn's disease but little is known of the final effector molecules responsible for matrix degradation. Although matrix metalloproteinases (MMPs) have been strongly implicated in tissue injury in Crohn's disease, their role in fistula formation is unknown. AIM: To determine the expression pattern of MMPs and tissue inhibitors of metalloproteinases (TIMPs) in fistulae of patients with Crohn's disease. PATIENTS AND METHODS: Resected fistula specimens were obtained from patients with Crohn's disease (n = 11) and classified according to the predominant histological features-that is, acute versus chronic inflammation. Patients with fistulae due to other diseases (n = 9) and normal colon (n = 5) served as controls. MMP and TIMP protein expression was measured by single or double labelled immunohistochemistry, and mRNA expression by in situ hybridisation. MMP activity was measured by gelatin zymography.
RESULTS: Compared with normal colon, strong MMP-3 expression was consistently observed in fistulae in Crohn's disease, irrespective of the stage of inflammatory activity. MMP-3 transcripts and protein were localised in large mononuclear cells and fibroblasts. MMP-9 transcripts and protein were expressed in granulocytes and only in fistulae with acute inflammation. Staining for MMP-1 and MMP-7 was weak and negative for MMP-10, whereas MMP-2 was equally expressed in normal colon and fistulae. TIMP-1, TIMP-2, and TIMP-3 expression was low in all samples. Similar expression patterns were found in fistulae of the disease control group. Fistulae also expressed active MMP-2 and MMP-9, as measured by gelatin zymography.
CONCLUSION: MMP-3 and MMP-9 are markedly upregulated in intestinal fistulae and may contribute to fistula formation through degradation of the extracellular matrix, irrespective of the underlying disease process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15082589      PMCID: PMC1774029          DOI: 10.1136/gut.2003.017442

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  38 in total

1.  Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease.

Authors:  E Louis; C Ribbens; A Godon; D Franchimont; D De Groote; N Hardy; J Boniver; J Belaiche; M Malaise
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Cost-utility of initial medical management for Crohn's disease perianal fistulae.

Authors:  K O Arseneau; S M Cohn; F Cominelli; A F Connors
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

3.  A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production.

Authors:  S L Pender; J M Fell; S M Chamow; A Ashkenazi; T T MacDonald
Journal:  J Immunol       Date:  1998-04-15       Impact factor: 5.422

4.  Vascular smooth muscle cells and pericytes express MMP-1, MMP-9, TIMP-1 and type I procollagen in inflammatory bowel disease.

Authors:  S Arihiro; H Ohtani; N Hiwatashi; A Torii; T Sorsa; H Nagura
Journal:  Histopathology       Date:  2001-07       Impact factor: 5.087

Review 5.  Management of internal fistulas in Crohn's disease.

Authors:  Cynthia Levy; William J Tremaine
Journal:  Inflamm Bowel Dis       Date:  2002-03       Impact factor: 5.325

6.  Matrix metalloproteinase inhibitor BB-3103 unlike the serine proteinase inhibitor aprotinin abrogates epidermal healing of human skin wounds ex vivo.

Authors:  Ursula Mirastschijski; Ulla Impola; Morten A Karsdal; Ulpu Saarialho-Kere; Magnus S Agren
Journal:  J Invest Dermatol       Date:  2002-01       Impact factor: 8.551

7.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

8.  Imbalance of stromelysin-1 and TIMP-1 in the mucosal lesions of children with inflammatory bowel disease.

Authors:  R B Heuschkel; T T MacDonald; G Monteleone; M Bajaj-Elliott; J A Smith; S L Pender
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

9.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

10.  Immunohistochemical detection of membrane-type-1-matrix metalloproteinase in colorectal carcinoma.

Authors:  R Kikuchi; T Noguchi; S Takeno; N Kubo; Y Uchida
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

View more
  52 in total

Review 1.  Fistulising Crohn's disease: MMPs gone awry.

Authors:  D Schuppan; T Freitag
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 2.  Immunopathogenesis of IBD: current state of the art.

Authors:  Heitor S P de Souza; Claudio Fiocchi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-12-02       Impact factor: 46.802

Review 3.  Matrix metalloproteases: underutilized targets for drug delivery.

Authors:  Deepali G Vartak; Richard A Gemeinhart
Journal:  J Drug Target       Date:  2007-01       Impact factor: 5.121

4.  The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis.

Authors:  Gábor Lakatos; Ferenc Sipos; Pál Miheller; István Hritz; Mária Zsófia Varga; Márk Juhász; Béla Molnár; Zsolt Tulassay; László Herszényi
Journal:  Pathol Oncol Res       Date:  2011-06-16       Impact factor: 3.201

5.  Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21.

Authors:  G Monteleone; R Caruso; D Fina; I Peluso; V Gioia; C Stolfi; M C Fantini; F Caprioli; R Tersigni; L Alessandroni; T T MacDonald; F Pallone
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

6.  Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis.

Authors:  Majken Lindholm; Tina Manon-Jensen; Gunvor Iben Madsen; Aleksander Krag; Morten Asser Karsdal; Jens Kjeldsen; Joachim Høg Mortensen
Journal:  Dig Dis Sci       Date:  2019-05-24       Impact factor: 3.199

Review 7.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

8.  Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice.

Authors:  Alfredo Santana; Carlos Medina; Maria-Cristina Paz-Cabrera; Federico Díaz-Gonzalez; Esther Farré; Antonio Salas; Marek-W Radomski; Enrique Quintero
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

9.  Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis.

Authors:  L Andresen; V L Jørgensen; A Perner; A Hansen; J Eugen-Olsen; J Rask-Madsen
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

10.  IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism.

Authors:  A Eken; A K Singh; P M Treuting; M Oukka
Journal:  Mucosal Immunol       Date:  2013-05-29       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.